CoChat

Diabetes Technology in People with Type 2 Diabetes: Novel Indications

Agarwal, Shubham, Galindo, Rodolfo J., Shah, Amy V., Abreu, Marconi · 2024 · Current Diabetes Reports
Cited by 12

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11892-024-01536-4

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 22

  1. UK Prospective Diabetes Study (UKPDS). Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53. https://doi.org/10.1016/S0140-6736(98)07019-6. · DOI · Paper page
  2. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431. · DOI · Paper page
  3. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008;358(24):2560–2572 https://doi.org/10.1056/NEJMoa0802987 · DOI · Paper page
  4. Galindo RJ, Trujillo JM, Low Wang CC, McCoy RG. Advances in the management of type 2 diabetes in adults. BMJ Med. 2023;2(1):e000372. https://doi.org/10.1136/bmjmed-2022-000372. · DOI
  5. Lingvay I, Agarwal S. A revolution in obesity treatment. Nat Med. 2023;29(10):2406–8. https://doi.org/10.1038/s41591-023-02538-7. · DOI
  6. • Galindo RJ, Aleppo G. Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology Diabetes Res Clin Pract. 2020;170:108502. https://doi.org/10.1016/j.diabres.2020.108502. This article covers the salient advances in CGM technology over time and provides tips on implementation of CGM in the medical office. · DOI · Paper page
  7. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7(2):562–78. https://doi.org/10.1177/193229681300700234. · DOI · Paper page
  8. Das SK, Nayak KK, Krishnaswamy PR, et al. Review—electrochemistry and other emerging technologies for continuous glucose monitoring devices. ECS Sensors Plus. 2022;1(3) https://doi.org/10.1149/2754-2726/ac7abb · DOI
  9. Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-world hypoglycemia avoidance with a continuous glucose monitoring system’s predictive low glucose alert. Diabetes Technol Ther. 2019;21(4):155–8. https://doi.org/10.1089/dia.2018.0359. · DOI · Paper page
  10. Reiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol. 2017;11(1):59–67. https://doi.org/10.1177/1932296816662047. · DOI · Paper page
  11. Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diab Vasc Dis Res. 2021;18(4):14791641211021374. https://doi.org/10.1177/14791641211021374. · DOI · Paper page
  12. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178–84. https://doi.org/10.2337/dc18-0166. · DOI · Paper page
  13. Ehrhardt N, Al ZE. Continuous glucose monitoring as a behavior modification tool. Clin Diabetes. 2020;38(2):126–31. https://doi.org/10.2337/cd19-0037. · DOI · Paper page
  14. Ananthanarayanan V, Mithun Haridas TP, Naveen R, et al. Reliable and affordable embedded system solution for continuous blood glucose maintaining system with wireless connectivity to blood glucose measuring system. IJCA Proceedings on Amrita International Conference of Women in Computing. 2013; AICWIC(2):36–43
  15. Boughton CK, Hovorka R. Automated insulin delivery in adults. Endocrinol Metab Clin North Am. 2020;49(1):167–78. https://doi.org/10.1016/j.ecl.2019.10.007. · DOI
  16. Cziraky MJ, Abbott S, Nguyen M, et al. A pragmatic clinical trial to compare the real-world effectiveness of V-Go versus standard delivery of insulin in patients with advanced type 2 diabetes. J Health Econ Outcomes Res. 2019 6(2):70–83. https://doi.org/10.36469/9731 · DOI
  17. Hundal R, Kowalyk S, Wakim A, Nikkel C, Sink Ii JH, Doyle M Multicenter real-world assessment of the effectiveness of V-Go wearable insulin delivery device in adult patients with type 2 diabetes (ENABLE Study): a retrospective analysis. Med Devices (Auckl). 2020;13:283–291 https://doi.org/10.2147/MDER.S265869 · DOI
  18. Bergenstal RM, Peyrot M, Dreon DM, et al. Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther. 2019;21(5):273–85. https://doi.org/10.1089/dia.2018.0298. · DOI · Paper page
  19. Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167–73. https://doi.org/10.1177/19322968211016513. · DOI
  20. Isaacs D, Kruger DF, Shoger E, Chawla H. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2023;41(2):198–207. https://doi.org/10.2337/cd22-0034. · DOI
  21. Habif S, Constantin A, Mueller L, et al. 126-LB: glycemic outcomes for people with type 1 and type 2 diabetes using control-IQ technology: real-world data from early adopters. Diabetes. 2020, 69(Supplement_1): 126–LB https://doi.org/10.2337/db20-126-lb · DOI
  22. Peters AL, Ahmann AJ, Hirsch IB, Raymond JK. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. J Endocr Soc. 2018;2(11):1214–25. https://doi.org/10.1210/js.2018-00262. · DOI

Cited by

Metadata

Authors
Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M.
Venue
Current Diabetes Reports
Published
2024-02-29
Volume
24
Issue
5
Pages
85-95
ISSN
  • 1534-4827
  • 1539-0829
Cited by
12
References
21
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes Technology in People with Type 2 Diabetes: Novel Indications. https://app.cochat.ai/papers/10.1007/s11892-024-01536-4
The paper
Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M. (2024). Diabetes Technology in People with Type 2 Diabetes: Novel Indications. Current Diabetes Reports. https://doi.org/10.1007/s11892-024-01536-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.